Scilex Holding (SCLX) Total Non-Current Liabilities (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Total Non-Current Liabilities of $522.2 million for Q1 2026, up 121.57% year-over-year from $235.7 million in Q1 2025, and down 9.43% on a QoQ basis from $576.6 million in Q4 2025.
Scilex Holding (SCLX) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Total Non-Current Liabilities for 7 consecutive years, with $522.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 121.57% year-over-year to $522.2 million; the TTM figure through Mar 2026 stood at $522.2 million (up 121.57% YoY), while the FY2025 annual figure was $576.6 million, up 102.59% from the prior year.
- Total Non-Current Liabilities came in at $522.2 million for Q1 2026 at Scilex Holding, down from $576.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $576.6 million in Q4 2025, with the low at $11.0 million in Q3 2022.
- Average Total Non-Current Liabilities over 5 years is $237.2 million, with a median of $272.7 million recorded in 2023.
- Across the five-year window, Total Non-Current Liabilities slumped 81.57% in 2022 and jumped 2090.64% in 2023, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $49.1 million in 2022, then jumped by 455.94% to $272.7 million in 2023, then advanced by 4.35% to $284.6 million in 2024, then soared by 102.59% to $576.6 million in 2025, then retreated by 9.43% to $522.2 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $522.2 million, $576.6 million, and $373.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 48.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.22 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 109.01 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -34.06 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 75.17 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 100.00 Mn |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 522.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 522.16 Mn |
| Dec 31, 2025 | 576.56 Mn |
| Sep 30, 2025 | 373.62 Mn |
| Jun 30, 2025 | 332.58 Mn |
| Mar 31, 2025 | 235.67 Mn |
| Dec 31, 2024 | 284.59 Mn |
| Sep 30, 2024 | 300.29 Mn |
| Jun 30, 2024 | 319.05 Mn |
| Mar 31, 2024 | 274.09 Mn |
| Dec 31, 2023 | 272.73 Mn |
| Sep 30, 2023 | 241.10 Mn |
| Jun 30, 2023 | 109.48 Mn |
| Mar 31, 2023 | 68.49 Mn |
| Dec 31, 2022 | 49.06 Mn |
| Sep 30, 2022 | 11.01 Mn |
| Jun 30, 2022 | 51.65 Mn |
| Mar 31, 2022 | 11.02 Mn |
| Dec 31, 2021 | 266.11 Mn |
| Sep 30, 2021 | 5.23 Mn |
| Jun 30, 2021 | 5.21 Mn |